Myers – Page 4 – Talk Bio

FDA Action Alert: Recent Developments on Unapproved Drugs and Prescription Drug Approvals

9 months ago talkbio0Tagged approvals, Azurity, Clinical action, Ionis, lexicon, Myers, Prescription procedure, squibb, unapproved, United States Food and Drug Administration

FDA Action Alert, Unapproved Drugs, Prescription Drug Approvals, Azurity Pharmaceuticals Inc., Bristol Myers Squibb, Ionis, Lexicon

Bristol Myers Squibb Announces Additional Layoffs in New Jersey Amid Cost-Cutting Efforts

10 months ago talkbio0Tagged cost-cutting, Drug Industry, Myers, New Jersey, squibb

Bristol Myers Squibb, layoffs, New Jersey, cost-cutting, pharmaceutical industry

Allogene Halts Leukemia CAR-T Trial Enrollment Due to Breyanzi Competition

10 months ago talkbio0Tagged Allogene, Breyanzi, CAR-T, cema-cel, Clinical Trials, leukemia, Myers, squibb

Allogene, CAR-T therapy, leukemia, Breyanzi, Bristol Myers Squibb, cema-cel, clinical trials

Bristol Myers Squibb Posts Strong Q3 Results, Boosts 2024 Guidance on Robust Sales of Legacy and New Drugs

10 months ago talkbio0Tagged Advice, Drug Industry, earnings, financial performance, Inheritance, Myers, squibb

Bristol Myers Squibb, Q3 earnings, 2024 guidance, legacy drugs, newer drugs, pharmaceutical industry, financial performance

Bristol Myers Squibb Invests $110 Million in T-Cell Therapy Pact with Prime Medicine

11 months ago talkbio0Tagged biotech, BMS, Burning Mouth Syndrome, ex vivo, Investments, Myers, pharmaceutical partnerships, Prime Medicine, squibb, T-cell therapy

Bristol Myers Squibb (BMS), Prime Medicine, T-cell therapy, Ex vivo therapies, Biotech investment, Pharmaceutical partnerships

Federal Judge Dismisses $6.4 Billion Lawsuit Against Bristol Myers Squibb Over Celgene Acquisition

12 months ago talkbio0Tagged BMS, Burning Mouth Syndrome, Celgene Acquisition, CVR, Drug Industry, federal, Judge, Legal Dispute, Myers, squibb

Bristol Myers Squibb (BMS), Celgene Acquisition, $6.4 Billion Lawsuit, Contingent Value Rights (CVR), Federal Judge Ruling, Pharmaceutical Industry, Legal Dispute

Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy

12 months ago talkbio0Tagged Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, New, psychiatric medication, Schizophrenia, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication

Bristol Myers Squibb Continues Layoffs in New Jersey, Cutting 79 More Jobs

12 months ago talkbio0Tagged BMS layoffs, cost-savings measures, Drug Industry, Jersey layoffs, Myers, squibb

Bristol Myers Squibb, BMS layoffs, New Jersey layoffs, pharmaceutical industry layoffs, cost-savings measures

Bristol Myers Squibb Continues Layoffs, Cutting 79 More Jobs in New Jersey Amid $1.5B Cost Reduction Effort

12 months ago talkbio0Tagged Drug Industry, Financial cost, Myers, New Jersey, squibb

Bristol Myers Squibb, layoffs, New Jersey, cost reduction, pharmaceutical industry

BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis

12 months ago talkbio0Tagged Alzheimer's Disease, Approved, KarXT, Mechanism (attribute), Muscarinic Agonists, Myers, Psychotic Disorders, Schizophrenia, squibb, United States Food and Drug Administration

KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.